CC BY 4.0 · Arq Neuropsiquiatr 2022; 80(11): 1112-1118
DOI: 10.1055/s-0042-1759759
Original Article

Frequency and economic burden of psychogenic non-epileptic seizures in patients applying for disability benefits due to epilepsy

Frequência e impacto econômico das crises psicogênicas não epilépticas em pacientes requerentes de aposentadoria por invalidez devido a epilepsia
1   Çukurova University, Faculty of Medicine, Department of Neurology, Epilepsy Unit, Adana, Türkiye.
,
1   Çukurova University, Faculty of Medicine, Department of Neurology, Epilepsy Unit, Adana, Türkiye.
,
1   Çukurova University, Faculty of Medicine, Department of Neurology, Epilepsy Unit, Adana, Türkiye.
,
2   Çukurova University, Faculty of Medicine, Department of Neurology, Adana, Türkiye.
,
1   Çukurova University, Faculty of Medicine, Department of Neurology, Epilepsy Unit, Adana, Türkiye.
,
2   Çukurova University, Faculty of Medicine, Department of Neurology, Adana, Türkiye.
,
1   Çukurova University, Faculty of Medicine, Department of Neurology, Epilepsy Unit, Adana, Türkiye.
› Author Affiliations

Abstract

Background Psychogenic non-epileptic seizures (PNES) resemble epileptic seizures and are often misdiagnosed as epilepsy.

Objective To investigate the frequency of PNES and to calculate the economic burden of the patients who admitted to video-electroencephalographicmonitoring (VEM) to obtain a diagnosis of epilepsy in order to apply for disability retirement.

Methods The present retrospective study included 134 patients who required disability reports between 2013 and 2019 and had their definite diagnoses after VEM. Following VEM, the patients were divided into three groups: epilepsy, PNES, and epilepsy + PNES.

Results In total, 22.4% (n = 30) of the patients were diagnosed with PNES, 21.6% (n = 29) with PNES and epilepsy, and 56% (n = 75), with epilepsy. The frequency of PNES among all patients was of 44% (n = 59). In patients with PNES alone, the annual cost of using anti-seizure medication was of 160.67 ± 94.04 dollars; for psychostimulant drugs, it was of 148.3 ± 72.48 dollars a year; and the mean direct cost for diagnostic procedures was of 582.9 ± 330.0 (range: 103.52–1601.3) dollars.

Conclusions Although it is challenging to determine the qualitative and quantitative total cost in these patient groups, early diagnosis and sociopsychological support will reduce the additional financial burden on the health system and increase the quality of life of the patients.

Resumo

Antecedentes As crises psicogênicas não epilépticas (CPNE) se assemelham a crises epilépticas, e muitas vezes são diagnosticadas erroneamente como epilepsia.

Objetivo Investigar a frequência de CPNE e calcular o impacto econômico dos pacientes internados para serem submetidos a monitoramento videoencefalográfico (MVE) para obter um diagnóstico de epilepsia e requerer aposentadoria por invalidez.

Métodos Este estudo retrospectivo incluiu 134 pacientes que solicitaram laudo médico de incapacidade entre 2013 e 2019, e obtiveram seus diagnósticos definitivos após serem submetidos a MEV. Os pacientes foram divididos em três grupos: epilepsia, CPNE, e epilepsia + CPNE.

Resultados Após o MEV, 22,4% (n = 30) dos pacientes foram diagnosticados com CPNE, 21,6% (n = 29), com CPNE + epilepsia, e 56%, com epilepsia. A frequência de CPNE entre todos os pacientes foi de 44% (n = 59). Em pacientes somente com CPNE, o custo anual do uso de anticonvulsivantes foi de US$ 160,67 ± 94,04; para os psicoestimulantes, o custo anual foi de US$ 148,3 ± 72,48; e a média do custo direto de procedimentos diagnósticos foi de US$ 582,9 ± 330,0 (variação: 103,52–1601,3).

Conclusões Embora seja um desafio determinar o custo total qualitativo e quantitativo nesses grupos de pacientes, o diagnóstico precoce e o apoio sociopsicológico reduzirão o impacto financeiro adicional ao sistema de saúde e aumentarão a qualidade de vida dos pacientes.



Publication History

Received: 01 December 2021

Accepted: 29 May 2022

Article published online:
28 December 2022

© 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 
  • References

  • 1 Papagno C, Montali L, Turner K. et al. Differentiating PNES from epileptic seizures using conversational analysis. Epilepsy Behav 2017; 76: 46-50
  • 2 Diprose W, Sundram F, Menkes DB. Psychiatric comorbidity in psychogenic nonepileptic seizures compared with epilepsy. Epilepsy Behav 2016; 56: 123-130
  • 3 Kerr WT, Janio EA, Braesch CT. et al. Identifying psychogenic seizures through comorbidities and medication history. Epilepsia 2017; 58 (11) 1852-1860
  • 4 Asadi-Pooya AA, Sperling MR. Epidemiology of psychogenic nonepileptic seizures. Epilepsy Behav 2015; 46: 60-65
  • 5 Szaflarski JP, Ficker DM, Cahill WT, Privitera MD. Four-year incidence of psychogenic nonepileptic seizures in adults in hamilton county, OH. Neurology 2000; 55 (10) 1561-1563
  • 6 Yon MI, Azman F, Tezer FI, Saygi S. The coexistence of psychogenic nonepileptic and epileptic seizures in the same patient is more frequent than expected: Is there any clinical feature for defining these patients?. Epilepsy Behav 2020; 105: 106940
  • 7 Specht U, Coban I, Bien CG, May TW. Risk factors for early disability pension in patients with epilepsy and vocational difficulties - Data from a specialized rehabilitation unit. Epilepsy Behav 2015; 51: 243-248
  • 8 Nemade D, Shivkumar V, Ferguson P, Singh J, Shah S. Psychosocial and Physiologic Characteristics of Patients with Non-epileptic Events: A Retrospective Study. Cureus 2020; 12 (01) e6767
  • 9 Asadi-Pooya AA, Bazrafshan M. Employment and disability status in patients with functional (psychogenic nonepileptic) seizures. Brain Behav 2021; 11 (03) e02016
  • 10 Kerr WT, Janio EA, Le JM. et al. Diagnostic delay in psychogenic seizures and the association with anti-seizure medication trials. Seizure 2016; 40: 123-126
  • 11 Martin RC, Gilliam FG, Kilgore M, Faught E, Kuzniecky R. Improved health care resource utilization following video-EEG-confirmed diagnosis of nonepileptic psychogenic seizures. Seizure 1998; 7 (05) 385-390
  • 12 Magee JA, Burke T, Delanty N, Pender N, Fortune GM. The economic cost of nonepileptic attack disorder in Ireland. Epilepsy Behav 2014; 33: 45-48
  • 13 Hong Z, Qu B, Wu XT, Yang TH, Zhang Q, Zhou D. Economic burden of epilepsy in a developing country: a retrospective cost analysis in China. Epilepsia 2009; 50 (10) 2192-2198
  • 14 Republic of Turkey, Ministry of Family and Social Services and Health, T.M.O. Regulation on disability assessment for adults. In, Official Gazette, 20 February, 2019, 30692.
  • 15 Sinha SR, Sullivan L, Sabau D. et al. American Clinical Neurophysiology Society Guideline 1: Minimum Technical Requirements for Performing Clinical Electroencephalography. J Clin Neurophysiol 2016; 33 (04) 303-307
  • 16 Benbadis SR, Agrawal V, Tatum IV WO. How many patients with psychogenic nonepileptic seizures also have epilepsy?. Neurology 2001; 57 (05) 915-917
  • 17 Asadi-Pooya AA, Valente K, Restrepo AD. et al. Adult-onset psychogenic nonepileptic seizures: A multicenter international study. Epilepsy Behav 2019; 98 (Pt A): 36-39
  • 18 Bodde NM, Lazeron RH, Wirken JM, van der Kruijs SJ, Aldenkamp AP, Boon PA. Patients with psychogenic non-epileptic seizures referred to a tertiary epilepsy centre: patient characteristics in relation to diagnostic delay. Clin Neurol Neurosurg 2012; 114 (03) 217-222
  • 19 Reuber M, Fernández G, Bauer J, Helmstaedter C, Elger CE. Diagnostic delay in psychogenic nonepileptic seizures. Neurology 2002; 58 (03) 493-495
  • 20 Begley CE, Famulari M, Annegers JF. et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000; 41 (03) 342-351
  • 21 Begley CE, Annegers JF, Lairson DR, Reynolds TF, Hauser WA. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994; 35 (06) 1230-1243
  • 22 Begley CE, Durgin TL. The direct cost of epilepsy in the United States: A systematic review of estimates. Epilepsia 2015; 56 (09) 1376-1387
  • 23 Scévola L, Teitelbaum J, Oddo S. et al. Psychiatric disorders in patients with psychogenic nonepileptic seizures and drug-resistant epilepsy: a study of an Argentine population. Epilepsy Behav 2013; 29 (01) 155-160
  • 24 Hantke NC, Doherty MJ, Haltiner AM. Medication use profiles in patients with psychogenic nonepileptic seizures. Epilepsy Behav 2007; 10 (02) 333-335
  • 25 Zanzmera P, Sharma A, Bhatt K. et al. Can short-term video-EEG substitute long-term video-EEG monitoring in psychogenic nonepileptic seizures? A prospective observational study. Epilepsy Behav 2019; 94: 258-263
  • 26 Bodde NM, Brooks JL, Baker GA. et al. Psychogenic non-epileptic seizures–definition, etiology, treatment and prognostic issues: a critical review. Seizure 2009; 18 (08) 543-553
  • 27 Bowman ES, Markand ON. Psychodynamics and psychiatric diagnoses of pseudoseizure subjects. Am J Psychiatry 1996; 153 (01) 57-63